Thomas Ross

Digene Corp. developed manufactured and market DNA and RNA tests. Its products are used for the detection, screening and monitoring of human diseases. The company was founded by Floyd E. Taub and Evan Jones in 1987 and was headquartered in Germantown, MD.

Digene Corp. developed manufactured and market DNA and RNA tests. Its products are used for the detection, screening and monitoring of human diseases. The company was founded by Floyd E. Taub and Evan Jones in 1987 and was headquartered in Germantown, MD.

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

Digene Corp. developed manufactured and market DNA and RNA tests. Its products are used for the detection, screening and monitoring of human diseases. The company was founded by Floyd E. Taub and Evan Jones in 1987 and was headquartered in Germantown, MD.

Digene Corp. developed manufactured and market DNA and RNA tests. Its products are used for the detection, screening and monitoring of human diseases. The company was founded by Floyd E. Taub and Evan Jones in 1987 and was headquartered in Germantown, MD.

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

Digene Corp. developed manufactured and market DNA and RNA tests. Its products are used for the detection, screening and monitoring of human diseases. The company was founded by Floyd E. Taub and Evan Jones in 1987 and was headquartered in Germantown, MD.

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

Digene Corp. developed manufactured and market DNA and RNA tests. Its products are used for the detection, screening and monitoring of human diseases. The company was founded by Floyd E. Taub and Evan Jones in 1987 and was headquartered in Germantown, MD.

Digene Corp. developed manufactured and market DNA and RNA tests. Its products are used for the detection, screening and monitoring of human diseases. The company was founded by Floyd E. Taub and Evan Jones in 1987 and was headquartered in Germantown, MD.

Digene Corp. developed manufactured and market DNA and RNA tests. Its products are used for the detection, screening and monitoring of human diseases. The company was founded by Floyd E. Taub and Evan Jones in 1987 and was headquartered in Germantown, MD.

Digene Corp. developed manufactured and market DNA and RNA tests. Its products are used for the detection, screening and monitoring of human diseases. The company was founded by Floyd E. Taub and Evan Jones in 1987 and was headquartered in Germantown, MD.

Digene Corp. developed manufactured and market DNA and RNA tests. Its products are used for the detection, screening and monitoring of human diseases. The company was founded by Floyd E. Taub and Evan Jones in 1987 and was headquartered in Germantown, MD.

Digene Corp. developed manufactured and market DNA and RNA tests. Its products are used for the detection, screening and monitoring of human diseases. The company was founded by Floyd E. Taub and Evan Jones in 1987 and was headquartered in Germantown, MD.